Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives

Folkman, 1990, What is the evidence that tumors are angiogenesis dependent?, J Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4 Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc Natl Acad Sci USA, 92, 5510, 10.1073/pnas.92.12.5510 Semenza, 1998, Hypoxia-inducible factor 1: master regulator of O2 homeostasis, Curr Opin Genet Dev, 8, 588, 10.1016/S0959-437X(98)80016-6 Bruick, 2001, A conserved family of prolyl-4-hydroxylases that modify HIF, Science, 294, 1337, 10.1126/science.1066373 Höpfl, 2004, HIFs and tumors—causes and consequences, Am J Physiol Regul Integr Comp Physiol, 286, R608, 10.1152/ajpregu.00538.2003 Goldberg, 1988, Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein, Science, 242, 1412, 10.1126/science.2849206 Semenza, 1991, Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene, Proc Natl Acad Sci USA, 88, 5680, 10.1073/pnas.88.13.5680 Wang, 1993, General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia, Proc Natl Acad Sci USA, 90, 4304, 10.1073/pnas.90.9.4304 Jiang, 1996, Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1, J Biol Chem, 271, 17771, 10.1074/jbc.271.30.17771 Michel, 2000, A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence, J Biomol Struct Dyn, 18, 169, 10.1080/07391102.2000.10506656 Carrero, 2000, Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha, Mol Cell Biol, 20, 402, 10.1128/MCB.20.1.402-415.2000 Richard, 1999, p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1, J Biol Chem, 274, 32631, 10.1074/jbc.274.46.32631 Hofer, 2001, Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1alpha activation cascade: implications for HIF-1alpha gene therapy, FASEB J, 15, 2715, 10.1096/fj.01-0546fje Aragonés, 2001, Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension, J Biol Chem, 276, 10548, 10.1074/jbc.M006180200 Huang, 1996, Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit, J Biol Chem, 271, 32253, 10.1074/jbc.271.50.32253 Jeong, 2002, Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation, Cell, 111, 709, 10.1016/S0092-8674(02)01085-1 Huang, 1998, Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin–proteasome pathway, Proc Natl Acad Sci USA, 95, 7987, 10.1073/pnas.95.14.7987 Pugh, 1997, Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit, J Biol Chem, 272, 11205, 10.1074/jbc.272.17.11205 Semenza, 1999, Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1, Annu Rev Cell Dev Biol, 15, 551, 10.1146/annurev.cellbio.15.1.551 Ema, 1997, A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development, Proc Natl Acad Sci USA, 94, 4273, 10.1073/pnas.94.9.4273 Tian, 1997, Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells, Genes Dev, 11, 72, 10.1101/gad.11.1.72 Tian, 1998, The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development, Genes Dev, 12, 3320, 10.1101/gad.12.21.3320 Makino, 2002, Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus, J Biol Chem, 277, 32405, 10.1074/jbc.C200328200 Gu, 1998, Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha, Gene Expr, 7, 205 Salceda, 1997, Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin–proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes, J Biol Chem, 272, 22642, 10.1074/jbc.272.36.22642 Kallio, 1997, Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor, Proc Natl Acad Sci USA, 94, 5667, 10.1073/pnas.94.11.5667 Lando, 2002, Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch, Science, 295, 858, 10.1126/science.1068592 Perkins, 1996, The role of MAP kinase in interleukin-3 stimulation of proliferation, Blood, 87, 3669, 10.1182/blood.V87.9.3669.bloodjournal8793669 Dameron, 1994, Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1, Science, 265, 1582, 10.1126/science.7521539 Bouvet, 1998, Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer, Cancer Res, 58, 2288 Blancher, 2001, Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway, Cancer Res, 61, 7349 Zundel, 2000, Loss of PTEN facilitates HIF-1-mediated gene expression, Genes Dev, 14, 391, 10.1101/gad.14.4.391 Jiang, 2001, Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1, Cell Growth Differ, 12, 363 Zhong, 2000, Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics, Cancer Res, 60, 1541 Krishnamachary, 2003, Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1, Cancer Res, 63, 1138 Treins, 2002, Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway, J Biol Chem, 277, 27975, 10.1074/jbc.M204152200 Laughner, 2001, HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression, Mol Cell Biol, 21, 3995, 10.1128/MCB.21.12.3995-4004.2001 Stiehl, 2002, Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway, FEBS Lett, 512, 157, 10.1016/S0014-5793(02)02247-0 Brahimi-Horn, 2005, Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications, Cell Signal, 17, 1, 10.1016/j.cellsig.2004.04.010 Srinivas, 1999, Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins, Biochem Biophys Res Commun, 260, 557, 10.1006/bbrc.1999.0878 Masson, 2001, Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation, EMBO J, 20, 5197, 10.1093/emboj/20.18.5197 Masson, 2003, HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels, J Cell Sci, 116, 3041, 10.1242/jcs.00655 Epstein, 2001, C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation, Cell, 107, 43, 10.1016/S0092-8674(01)00507-4 Huang, 2002, Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3, J Biol Chem, 277, 39792, 10.1074/jbc.M206955200 Berra, 2003, HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia, EMBO J, 22, 4082, 10.1093/emboj/cdg392 Ivan, 2001, HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science, 292, 464, 10.1126/science.1059817 Jaakkola, 2001, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796 Krek, 2000, VHL takes HIF's breath away, Nat Cell Biol, 2, E121, 10.1038/35017129 Jung, 2003, Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein, J Biol Chem, 278, 7445, 10.1074/jbc.M209804200 Cockman, 2000, Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein, J Biol Chem, 275, 25733, 10.1074/jbc.M002740200 Kamura, 2000, Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex, Proc Natl Acad Sci USA, 97, 10430, 10.1073/pnas.190332597 Krieg, 2000, Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function, Oncogene, 19, 5435, 10.1038/sj.onc.1203938 Ohh, 2000, Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein, Nat Cell Biol, 2, 423, 10.1038/35017054 Tanimoto, 2000, Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein, EMBO J, 19, 4298, 10.1093/emboj/19.16.4298 Kim, 2001, Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes, Nat Med, 7, 437, 10.1038/86507 Sang, 2002, Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP, Mol Cell Biol, 22, 2984, 10.1128/MCB.22.9.2984-2992.2002 Dames, 2002, Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response, Proc Natl Acad Sci USA, 99, 5271, 10.1073/pnas.082121399 Freedman, 2002, Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha, Proc Natl Acad Sci USA, 99, 5367, 10.1073/pnas.082117899 Hewitson, 2002, Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family, J Biol Chem, 277, 26351, 10.1074/jbc.C200273200 Mahon, 2001, FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity, Genes Dev, 15, 2675, 10.1101/gad.924501 Metzen, 2003, Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing, J Cell Sci, 116, 1319, 10.1242/jcs.00318 Chan, 2002, Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha, J Biol Chem, 277, 40112, 10.1074/jbc.M206922200 Isaacs, 2002, Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway, J Biol Chem, 277, 29936, 10.1074/jbc.M204733200 Katschinski, 2002, Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity, J Biol Chem, 277, 9262, 10.1074/jbc.M110377200 Sodhi, 2000, The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha, Cancer Res, 60, 4873 Minet, 2001, Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation, Free Radic Biol Med, 31, 847, 10.1016/S0891-5849(01)00657-8 Hur, 2001, Mitogen-activated protein kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha, Mol Pharmacol, 59, 1216, 10.1124/mol.59.5.1216 Suzuki, 2001, Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia, Oncogene, 20, 5779, 10.1038/sj.onc.1204742 Forsythe, 1996, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Mol Cell Biol, 16, 4604, 10.1128/MCB.16.9.4604 Olsson, 2006, VEGF receptor signalling—in control of vascular function, Nat Rev Mol Cell Biol, 7, 359, 10.1038/nrm1911 Jensen, 2006, Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas, J Neurooncol, 78, 233, 10.1007/s11060-005-9103-z Bos, 2001, Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis, J Natl Cancer Inst, 93, 309, 10.1093/jnci/93.4.309 Maxwell, 1997, Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth, Proc Natl Acad Sci USA, 94, 8104, 10.1073/pnas.94.15.8104 Tang, 2004, Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis, Cancer Cell, 6, 485, 10.1016/j.ccr.2004.09.026 Das, 2005, A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma, Cancer Res, 65, 7267, 10.1158/0008-5472.CAN-04-4575 Gerber, 1997, Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia, J Biol Chem, 272, 23659, 10.1074/jbc.272.38.23659 Ryan, 1998, HIF-1 alpha is required for solid tumor formation and embryonic vascularization, EMBO J, 17, 3005, 10.1093/emboj/17.11.3005 Burri, 2003, Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy, Int J Radiat Oncol Biol Phys, 56, 494, 10.1016/S0360-3016(02)04579-0 Schindl, 2002, Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer, Clin Cancer Res, 8, 1831 Birner, 2001, Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy, Clin Cancer Res, 7, 1661 Sivridis, 2002, Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma, Cancer, 95, 1055, 10.1002/cncr.10774 Takahashi, 2003, Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach, Oncol Rep, 10, 797 Koukourakis, 2001, Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy, Cancer Res, 61, 1830 Koukourakis, 2001, Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy, Clin Cancer Res, 7, 3399 Giatromanolaki, 2001, Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival, Br J Cancer, 85, 881, 10.1054/bjoc.2001.2018 Beasley, 2002, Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients, Cancer Res, 62, 2493 Volm, 2000, Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer, Anticancer Res, 20, 1527 Melillo, 2004, HIF-1: a target for cancer, ischemia and inflammation—too good to be true?, Cell Cycle, 3, 154, 10.4161/cc.3.2.689 Yeo, 2004, New anticancer strategies targeting HIF-1, Biochem Pharmacol, 68, 1061, 10.1016/j.bcp.2004.02.040 Giaccia, 2003, HIF-1 as a target for drug development, Nat Rev Drug Discov, 2, 803, 10.1038/nrd1199 Semenza, 2003, Targeting HIF-1 for cancer therapy, Nat Rev Cancer, 3, 721, 10.1038/nrc1187 Brown, 1996, Hypoxia-specific cytotoxins in cancer therapy, Semin Radiat Oncol, 6, 22, 10.1016/S1053-4296(96)80033-6 Post, 2004, Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors, Clin Cancer Res, 10, 8603, 10.1158/1078-0432.CCR-04-1432 Post, 2003, A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy, Oncogene, 22, 2065, 10.1038/sj.onc.1206464 Birner, 2000, Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis, Anticancer Res, 20, 2981 Bos, 2003, Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma, Cancer, 97, 1573, 10.1002/cncr.11246 Zagzag, 2000, Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression, Cancer, 88, 2606, 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.3.CO;2-N Belozerov, 2005, Hypoxia inducible factor-1: a novel target for cancer therapy, Anticancer Drugs, 16, 901, 10.1097/01.cad.0000180116.85912.69 Welsh, 2004, Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha, Mol Cancer Ther, 3, 233, 10.1158/1535-7163.233.3.3 Koh, 2008, Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha, Mol Cancer Ther, 7, 90, 10.1158/1535-7163.MCT-07-0463 Welsh, 2003, Hypoxia inducible factor as a cancer drug target, Curr Cancer Drug Targets, 3, 391, 10.2174/1568009033481732 Kaelin, 2002, Molecular basis of the VHL hereditary cancer syndrome, Nat Rev Cancer, 2, 673, 10.1038/nrc885 Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, 3, 391, 10.1038/nrd1381 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Hudson, 2002, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin, Mol Cell Biol, 22, 7004, 10.1128/MCB.22.20.7004-7014.2002 Hudes, 2007, Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Motzer, 2008, RAD001 vs. placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-III study, J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.lba5026 Papandreou, 2006, HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption, Cell Metab, 3, 187, 10.1016/j.cmet.2006.01.012 Brown, 2004, Exploiting tumour hypoxia in cancer treatment, Nat Rev Cancer, 4, 437, 10.1038/nrc1367 Cairns, 2007, Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy, Proc Natl Acad Sci USA, 104, 9445, 10.1073/pnas.0611662104 Takabuchi, 2004, The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway, Biochem Biophys Res Commun, 324, 417, 10.1016/j.bbrc.2004.09.064 Melillo, 2006, Meeting report: exploiting the tumor microenvironment for therapeutics, Cancer Res, 66, 4558, 10.1158/0008-5472.CAN-06-0069 Rapisarda, 2004, Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications, Cancer Res, 64, 1475, 10.1158/0008-5472.CAN-03-3139 Beppu, 2005, Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells, Cancer Res, 65, 4775, 10.1158/0008-5472.CAN-04-3332